false 0001591165 0001591165 2023-12-21 2023-12-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 21, 2023

 

Innoveren Scientific, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   001-36763   46-3312262

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

151 W4th St., Ste 223,

Cincinnati, OH

   45202
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:

(844) 633-6839

 

201 E Kennedy Blvd, Suite 700 Tampa, FL, 33602

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: Common Stock

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure

 

On December 21, 2023, Innoveren Scientific, Inc. (the “Company”) issued an investor presentation. A copy of the investor presentation is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 8.01 Other Events.

 

The Company changed its executive offices to 151 W4th St., Ste 223, Cincinnati, OH 45202.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

The following exhibits are filed as part of this report:

 

Item 9.01 Exhibits

 

Exhibit No.   Description
99.1   Investor Presentation dated December 21, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Innoveren Scientific, Inc.
     
Date: December 21, 2023 By: /s/ Jeremy Daniel
    Jeremy Daniel
    Chief Financial Officer

 

 

 

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

v3.23.4
Cover
Dec. 21, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 21, 2023
Entity File Number 001-36763
Entity Registrant Name Innoveren Scientific, Inc.
Entity Central Index Key 0001591165
Entity Tax Identification Number 46-3312262
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 151 W4th St.,
Entity Address, Address Line Two Ste 223,
Entity Address, City or Town Cincinnati
Entity Address, State or Province OH
Entity Address, Postal Zip Code 45202
City Area Code (844)
Local Phone Number 633-6839
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more H CYTE (QB) Charts.
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more H CYTE (QB) Charts.